Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

8

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Tyrosine-protein kinase JAK1

1

Tyrosine-protein kinase JAK2

1

Tyrosine-protein kinase JAK3

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1998

2

2001

1

2002

1

2005

1

2009

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Rheumatoid arthritis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Secondary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pfizer|National Institutes of Health

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Protein

8

Chemical

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

EVMPD

9

FDA UNII

9

LIVERTOX

9

NCI_THESAURUS

9

NDF-RT

9

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

5

CYTOKINE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

8

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

IMMUNOSUPPRESSANTS

8

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

IMMUNOSUPPRESSANTS

8

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Tumor necrosis factor alpha (TNF-a) inhibitors

4

Interleukin inhibitors

2

Selective immunosuppressants

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

9

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "LiverTox|Immunomodulatory|Rheumatic Disease" in comments (approximate match)

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Tofacitinib

87LA6FU830

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2012

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Tyrosine-protein kinase JAK1

Tyrosine-protein kinase JAK3

Tyrosine-protein kinase JAK2

Conditions:

Rheumatoid arthritis

Tofacitinib is an orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of tra...

nscription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. Tofacitinib was discovered and developed by the National Institutes of Health and Pfizer. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and the treatment of psoriasis and ulcerative colitis. Patients treated with tofacitinib (XELJANZ) are at increased risk for developing serious infections that may lead to hospitalization or death and adverse reactions. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

TOCILIZUMAB

I031V2H011

Subunit 1 (448) Similarity Search Subunit 2 (448) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (448) Similarity Search Subunit 2 (448) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2013)

First approved in 2010

Class:

PROTEIN

GOLIMUMAB

91X1KLU43E

Subunit 1 (456) Similarity Search Subunit 2 (456) Similarity Search Subunit 3 (215) Similarity Search Subunit 4 (215) Similarity Search

Export Data
Sequence Search

Subunit 1 (456) Similarity Search Subunit 2 (456) Similarity Search Subunit 3 (215) Similarity Search Subunit 4 (215) Similarity Search

Status:

US Approved Rx (2013)

First approved in 2009

Class:

PROTEIN

ABATACEPT

7D0YB67S97

Subunit 1 (383) Similarity Search Subunit 2 (383) Similarity Search

Export Data
Sequence Search

Subunit 1 (383) Similarity Search Subunit 2 (383) Similarity Search

Status:

US Approved Rx (2005)

First approved in 2005

Class:

PROTEIN

ADALIMUMAB

FYS6T7F842

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2021)

First approved in 2002

Class:

PROTEIN

ANAKINRA

9013DUQ28K

Subunit 1 (153) Similarity Search

Export Data
Sequence Search

Subunit 1 (153) Similarity Search

Status:

US Approved Rx (2001)

First approved in 2001

Class:

PROTEIN

INFLIXIMAB

B72HH48FLU

Subunit 1 (450) Similarity Search Subunit 2 (450) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (450) Similarity Search Subunit 2 (450) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2019)

First approved in 1998

Class:

PROTEIN

ETANERCEPT

OP401G7OJC

Subunit 1 (467) Similarity Search Subunit 2 (467) Similarity Search

Export Data
Sequence Search

Subunit 1 (467) Similarity Search Subunit 2 (467) Similarity Search

Status:

US Approved Rx (1998)

First approved in 1998

Class:

PROTEIN

CERTOLIZUMAB

G6ADW90R16

Subunit 1 (229) Similarity Search Subunit 2 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (229) Similarity Search Subunit 2 (214) Similarity Search

Status:

Possibly Marketed Outside US

Class:

PROTEIN

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1